THN102

THN102 is an experimental combination drug that brings together modafinil, a widely used wakefulness-promoting medication, with a low dose of flecainide ^[1][2]. Flecainide is best known as a heart-rhythm drug, but at the low doses used here it is intended to act on the brain rather than the heart, inhibiting the connexins that form gap junctions between astrocytes, the star-shaped support cells of the nervous system ^[1]. The combination was developed by the French company Theranexus as part of a broader strategy of adding a glial-acting compound to an existing neurological drug in order to amplify its effect ^[1][2].

The rationale grew out of preclinical work showing that modafinil modulates the coupling between astrocytes that is built from connexins, and that adding flecainide, which inhibits astroglial connexins such as Cx30 and Cx43, enhanced modafinil's wake-promoting and pro-cognitive effects in rodents ^[1]. In narcoleptic mice lacking orexin, the modafinil-flecainide combination sharply reduced the abnormal transitions into rapid-eye-movement sleep that mimic narcoleptic episodes ^[1]. Brain-imaging studies in rats later showed that THN102 increased activity in cortical, striatal, and amygdala regions involved in the sleep-wake cycle, emotion, and cognition, more than either drug given alone ^[2].

Modafinil itself is a first-line therapy for the excessive daytime sleepiness of narcolepsy and acts through a complex neurochemistry that raises signaling by dopamine and other transmitters in wake-regulating brain regions ^[3]. THN102 was advanced into clinical testing as a potential improvement on modafinil for narcolepsy and has also been explored for sleepiness in other conditions ^[2]. It remains an investigational agent that is not approved for medical use, and the concept of pairing a neuronal drug with a glial-acting partner is still under study ^[1][2].

This is an investigational combination; modafinil's own profile (headache, anxiety, insomnia, appetite loss, rare serious rash) applies, and flecainide is a real antiarrhythmic that is only safe here because the dose is far below cardiac-active levels. Not an approved product, and the flecainide component means heart considerations should never be hand-waved. Research use only.

THN102 is a proprietary fixed combination of modafinil with a low, sub-antiarrhythmic dose of flecainide, developed by the French biotech Theranexus, which was founded in 2013 as a spin-out from the CEA (French Alternative Energies and Atomic Energy Commission) to exploit glial connexin modulation. The rationale is that low-dose flecainide acts on glial connexins to potentiate modafinil's wake-promoting effect, and a 40-hour sleep-deprivation study in healthy volunteers, published by Sauvet and colleagues in 2019, reported gains in vigilance and cognition over modafinil alone.

Theranexus advanced THN102 into Phase II for excessive daytime sleepiness, including a narcolepsy trial and a Parkinson's disease trial (NCT03624920) run across sites in France, Hungary, the Czech Republic, Germany, and the United States. In the roughly 75-patient Parkinson's study, the 200 mg modafinil / 2 mg flecainide arm reached statistical significance versus placebo on daytime sleepiness while remaining well tolerated. The candidate has remained an investigational, unapproved compound.